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Common femoral artery occlusive disease:
Contemporary results following surgical
endarterectomy
Jeanwan L. Kang, MD, Virendra I. Patel, MD, Mark F. Conrad, MD, Glenn M. LaMuraglia, MD,
Thomas K. Chung, MA, and Richard P. Cambria, MD, Boston, Mass
Objective: Proliferation of endovascular techniques with perceived reduction in treatment morbidity repetitively question
the precept that surgical endarterectomy is the preferred treatment for occlusive disease of the common femoral artery
(CFA). This study details a contemporary experience with common femoral endarterectomy (CFE) with and without
concomitantly performed endovascular therapies.
Methods: Technical, hemodynamic, and clinical success of CFE performed between 2002 and 2005 were determined
according to the Society of Vascular Surgery reporting standards. Primary and assisted patencies of the CFA segment,
freedom from reintervention in the ipsilateral limb, and survival were assessed using Kaplan-Meier life-table analysis.
Multivariate analysis was performed to evaluate factors associated with patency and survival.
Results: CFE was performed on 65 limbs in 58 patients (mean age 71  10; male 77%; diabetes 28%; creatinine > 1.5
mg/dL 19%). Forty-four cases (68%) were performed for claudication, and 21 cases (32%) for critical limb ischemia.
Thirty-seven cases (57%) were performed as a hybrid procedure wherein concomitant endovascular interventions were
performed. Twenty iliac (TASC II A-30%; B-35%; C-20%; D-15%) and 25 femoropopliteal (TASC II A-24%; B-60%;
C-12%; D-4%) lesions were treated. Technical success was achieved in 100% of the cases. Hemodynamic success was
achieved in 95% of the cases with mean postoperative increase in ankle-brachial index (ABI) of 0.24  0.24. All but one
patient (98.5%) had improvement in symptoms and/or ABI. Average hospital stay was 3.2 days (range 1-12 days). There
were 3 (5%) major complications requiring reintervention (early failure secondary to untreated inflow lesion, hematoma,
and wound infection), six (9%) minor complications which were treated conservatively (five wound infections, one lymph
leak), and no perioperative mortality. With a mean follow-up period of 27 months (range 1-58 months), 1- and 5-year
primary patencies were 93% and 91%, respectively. Assisted patency was 100% at both time points. There was no difference
in patencies between CFE performed alone or as a hybrid procedure. Multivariate analysis showed congestive heart failure
(CHF) as the only predictor of primary failure (odds ratio [OR] 18.5 [2.6-142.9]; P  .004). Freedom from
reintervention in the ipsilateral limb was 82% at 1 year and 78% at 5 years, with CHF again as the only predictor of
reintervention (OR 5.3 [1.4-19.6]; P .012). Survival was 89% at 1 year and 70% at 5 years. There were no amputations.
Conclusions: These data suggest CFE should remain the standard of care for occlusive disease of the CFA. Its safety and
efficacy establish a standard for comparison with emerging endovascular therapies. ( J Vasc Surg 2008;48:872-7.)Surgical endarterectomy has been the standard treat-
ment for occlusive disease of the common femoral artery
(CFA) for over 50 years. However, recent advances in
endovascular therapy have led to increasing number of
patients undergoing percutaneous treatment for their CFA
disease. The rationale for such change in treatment para-
digm has been perceived lower morbidity and mortality,
shorter hospital stay, and quicker recovery to normal func-
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872tional status in exchange for lower, but acceptable, patency
rates associated with endovascular treatment. While such a
shift in treatment paradigm for disease in the superficial
femoral artery (SFA) is both justified and appropriate in
both our experience and that of others,1-6 there are scant
data to shift the focus of CFA disease treatment away from
an open surgical approach. Early studies examining the
efficacy of CFA percutaneous transluminal angioplasty
(PTA) demonstrate variable results.1,7,8 Indeed, some data
suggest that CFA PTA may not be as effective as that for
SFA.1,8 More recently, there have been reports of successful
stent placements for disease in the CFA.9,10 Most surgeons
believe, however, that the potential problems of placing a
stent in the CFA, including risk of stent fracture and intimal
hyperplasia,11,12 possible need to sacrifice collaterals pro-
vided by the profunda, and potential compromise in future
surgical options in patients who often present with multi-
level disease, outweigh the presumed advantages of an
endovascular approach. In addition to PTA and stent place-
ment, other modalities such as cryoplasty and atherectomy
are being considered for treatment of occlusive disease in
the CFA.13
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efficacy of common femoral endarterectomy (CFE) in a
contemporary series and establish a standard for compari-
son with emerging endovascular therapies.
METHODS
Patients and data collection. The Institutional Re-
view Board of the Massachusetts General Hospital ap-
proved the clinical protocol. Between January 1, 2002 and
December 31, 2005, 65 CFEs were performed on 58
symptomatic patients with occlusive disease of the CFA at
theMassachusetts General Hospital. These were performed
either as an isolated procedure or as a hybrid procedure
where concurrent endovascular treatment for additional
lesion(s) in the ipsilateral limb was carried out. All proce-
dures were performed by a vascular surgeon in an endovas-
cular operating room suite with fixed imaging. CFE was
performed using standard technique. External control of
SFA and profunda femoris artery (PFA) was routine with
the distal extent of the dissection determined by individual
anatomy. A longitudinal arteriotomy was made extending
from well proximal to the disease onto (typically) the
proximal SFA, or directly onto the PFA when SFA was
occluded. PFA orifice lesions were often present and these
were usually treated using eversion endarterectomy. Patch
angioplasty was then performed using Dacron, polytetra-
fluoroethylene, or bovine pericardium patch in all but two
cases. For the hybrid procedures, CFE was performed prior
to the endovascular component of the case in all but two
instances. Following CFE, access was obtained through the
patch under direct vision in the ipsilateral limb; hydrophilic
guidewires were used under fluoroscopic control to ensure
true lumen entry. In cases where both iliac and femoropop-
liteal endovascular treatments were performed, iliac lesions
were treated first, then the sheath was partially removed and
redirected antegrade to treat the outflow lesions. Intraop-
erative angiography and/or pulse volume recording (PVR)
was performed to confirm satisfactory revascularization at
the conclusion of each case.
Patients who had previous CFE, previous or concurrent
bypass grafts utilizing CFA for either the proximal or distal
anastomosis, CFE as part of endovascular aortic aneurysm
repair or remote endarterectomy of the SFA were excluded.
Also excluded were patients who presented emergently
with acute limb ischemia or dissection.
Retrospective review of prospectively gathered com-
puter based data, office notes, operative notes, laboratory
data, radiologic studies, and angiograms were performed to
gather demographic, and perioperative data. Clinical cate-
gory at the time of presentation was determined according
to the Rutherford classification as specified by the Society
for Vascular Surgery/American Association for Vascular
Surgery reporting standards.14 Patients were considered to
have a history of coronary artery disease even if they were
asymptomatic after undergoing coronary artery angioplasty
or bypass grafting. Chronic renal failure was defined as
serum creatinine level of 1.5 mg/dL. All patients under-went preoperative angiogram and/or magnetic resonance
angiography (MRA).
Postprocedure follow-up. All outpatient clinic visits,
hospital admissions, relevant radiologic studies, lower ex-
tremity noninvasive studies, and angiograms were re-
viewed. Patients were routinely evaluated at 4 to 6 weeks
following the procedure by the individual surgeons along
with lower extremity noninvasive studies by ankle-brachial
index (ABI), PVR, or both. Patients were then followed
every 6 to 12 months according to the discretion of the
treating surgeon. Patients who were lost to follow-up were
contacted by telephone by a physician and appropriate data
gathered. Patients with worsening clinical symptoms, phys-
ical examinations, and/or noninvasive studies underwent
diagnostic angiography. Further interventions were then
carried out at the discretion of the vascular surgeon.
Definitions and endpoints. Technical success of CFE
was determined by intraoperative PVR and/or angiogra-
phy. For patients undergoing PTAs, an angiography dem-
onstrating 20% residual stenosis was considered techni-
cally successful. Hemodynamic success was defined as an
increase in ABI of  0.10 or improvement in plethysmo-
graphic tracing by  5 mm according to the Society for
Vascular Surgery/American Association for Vascular Sur-
gery reporting standards.14 Clinical success was defined
according to the American Heart Association (AHA) clas-
sification (Table I).15
In this study, patency refers to the status of the CFE
and does not refer to the patency of distal revasculariza-
tions. Primary patency was defined as patency of the CFA
without evidence of restenosis or need for reintervention.
Primary-assisted patency was defined as a patent CFA that
needed at least one reintervention for recurrent stenosis.14
Freedom from reintervention was defined as freedom from
reintervention anywhere in the ipsilateral limb. Iliac and
femoropopliteal lesions were assigned a TransAtlantic
InterSociety Consensus II (TASC II).16 Major amputa-
tions included above-knee and below-knee amputations,
while minor amputations included transmetatarsal amputa-
Table I. American Heart Association guidelines for
clinical improvement
Grade Clinical description
3 Markedly improved; ABI  0.9 and no ischemic
symptoms
2 Moderately improved; ABI increase  0.1 but not
normal, and increase by one category
1 Minimally improved; ABI increase 0.1 but not normal,
or increase by one category
0 No change
1 Mildly worse; no category decrease or ABI increase
 0.1
2 Moderately worse; one category worse or unexpected
minor amputation
3 Markedly worse; more than one category worse or
unexpected major amputation
ABI, Ankle-brachial index.tions and toe amputations.
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as any complications or mortality occurring within 30 days
of the operation. Major complication was defined as one
where reintervention or readmission was required, whereas
minor complication was defined as one treated without an
intervention in an outpatient setting. Survival data was
obtained from hospital records, the Social Security Data-
base, or direct communication with the patient or the
patient’s family member.
Statistical analysis. Statistical analysis was performed
using SPSS version 15.0 (SPSS Inc, Chicago, Ill). Patency
and survival analyses were performed using the Kaplan-
Meier life-table analysis. Analyses of dichotomous and con-
tinuous variables were performed using Fisher exact t and
2. Multiple logistic regression was used to evaluate factors
associated with procedural failure and death. P value of less
than .05 was considered statistically significant.
RESULTS
Sixty-five CFEs were performed on 58 patients during
the study period. Demographic and clinical features of the
study group are shown in Table II. Twenty-eight percent
(18/65) of the patients had diabetes (six patients with
insulin-dependent diabetes) and 19% had chronic renal
failure of which only one patient was dialysis-dependent.
Forty-four CFEs (68%) were performed for claudication
while the remaining 21 (32%) were performed for critical
limb ischemia (CLI), as shown in Table III.
Thirty-seven procedures (57%) were performed as a
hybrid procedure with concurrent endovascular interven-
tion(s) on the ipsilateral limb (30% CLI). Eight of these
hybrid procedures were performed for lesions in both iliac
and femoral/popliteal arteries whereas 12 were performed
for iliac lesions only and 17 for femoral/popliteal lesions
only. Of 20 iliac lesions treated, 14 (70%) were treated with
stents and nine of 25 (36%) femoropopliteal lesions were
Table II. Demographic and clinical features
Characteristic % (N) Mean  SD [range]
Age 71.4  9.6 [47-88]
Gender
Male 76.9 (50/65)
Female 23.1 (15/65)
HTN 95.4 (62/65)
CAD 73.8 (48/65)
HLD 81.5 (53/65)
COPD 29.2 (19/65)
CHF 7.7 (5/65)
Current smoker 20.0 (13/65)
Past smoker 72.3 (47/65)
Home O2 1.5 (1/65)
CRI 18.5 (12/65)
DM 27.7 (18/65)
HTN, Hypertension; CAD, coronary artery disease; HLD, hyperlipidemia;
COPD, chronic obstructive pulmonary disease; CHF, congestive heart fail-
ure;O2, oxygen;CRI, chronic renal insufficiency defined as serum creatinine
 1.5 mg/dL; DM, diabetes mellitus.treated with stents. The remaining lesions were treated withballoon angioplasty alone. Lesion characteristics features
are summarized in Table IV. In addition, there were 25
cases with known femoropopliteal lesions which were not
treated at the time of CFE. Of these, 56% were in claudi-
cants and 44% in patients with CLI. Nearly 50% of these
untreated femoropopliteal lesions were TASC II C and D
lesions.
Technical success was achieved in 100% with no intra-
operative complications. The average operating time was
3.0  0.8 hours (range 1.0 to 5.0 hours). Twenty-seven
cases (42%) were performed under general anesthesia, 30
(47%) under epidural anesthesia, and seven (11%) under
local anesthesia with intravenous sedation. The average
hospital stay was 3.2  1.7 days (range 1-12).
There were nine (13.8%) complications overall, three
(5%) of which were major complications requiring reinter-
vention. The first major complication was in a patient with
an untreated external iliac artery (EIA) stenosis who lost
distal pulses following CFE and required PTA and stenting
on post-operative day 4. Preoperative angiography per-
formed one day prior to her CFE had shown a 3 cm EIA
stenosis. However, this was not treated at the time of her
CFE because the patient was thought to have adequate
inflow at the conclusion of the case. The second major
complication was an expanding hematoma requiring evac-
uation on post-operative day 0. The last major complica-
tion was an infected pseudoaneurysm requiring return to
the operating room 1 month following the original proce-
dure. This patient underwent removal of the infected Da-
cron patch and saphenous vein patch angioplasty with a
rotational sartorius muscle flap with successful resolution
and patent reconstruction at 14 months following the
original procedure. The remaining six minor complications
Table III. Clinical presentation according to Rutherford
classification
Rutherford category N (%)
1. Mild claudication 0 (0)
2. Moderate claudication 10 (15.4)
3. Severe claudication 34 (52.3)
4. Ischemic rest pain 13 (20.0)
5. Minor tissue loss 8 (12.3)
6. Major tissue loss 0 (0)
Table IV. Anatomic features of lesions treated
TASC II class Total (%)
Iliac lesions A 6 (30)
B 7 (35)
C 4 (20)
D 3 (15)
Femoropopliteal lesions A 6 (24)
B 15 (60)
C 3 (12)
D 1 (4)included five superficial wound infections and one lymph
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perioperative deaths occurred.
Hemodynamic success was achieved in 95% (62/65)with
a mean postoperative increase in resting ABI of 0.24  0.24
and a mean postoperative increase in exercise ABI of 0.34 
0.33. The mean preoperative resting ABI was 0.53  0.28,
and themean postoperative restingABIwas 0.790.22. The
mean preoperative exercise ABI was 0.28  0.27, and the
mean postoperative exercise ABI was 0.72 0.41.
Ninety-nine percent of the procedures resulted in an
improvement in clinical status with 25% (16/65) having
grade 3 improvement, 66% (43/65) grade 2, and 8%
(5/65) grade 1, according to the AHA classification (Table
I). Only one patient had no improvement (grade 0). This
occurred in a patient with history of very aggressive periph-
eral vascular disease who had undergone multiple percuta-
neous interventions, including bilateral SFA balloon angio-
plasties within 6 months prior to his CFE. Angiography
performed 3 months following the procedure showed a
severe stenosis at the PFA origin as well as new lesions in the
mid-external iliac artery and the SFA. This patient under-
went PTA and stenting of his iliac and SFA lesions as well as
PTA of his PFA origin with subsequent improvement in his
symptoms. No patient’s condition was made worse after
the procedure. Six of eight foot lesions (75%) were com-
pletely healed. In one patient, the wound was improving
but the patient died secondary to an unknown cause 5
months following CFE. One patient failed to heal his
wound following CFE. Angiography showed patent CFA
but a 16 cm SFA occlusion with a three-vessel runoff. The
treating surgeon had elected not to treat the SFA occlusion
at the time of his CFE. Further treatment was deferred
secondary to patient’s multiple medical problems including
end-stage renal failure and the patient died 4 months
following CFE.
With a mean follow-up period of 27  14 months
(range 1-58), 1- and 5-year primary patency rates were 93%
and 91%, respectively (Fig and Appendix I, online only).
Primary-assisted patencies were 100% at both time points
(Appendix I, online only). The five primary failures oc-
curred at 3, 5, 8, 12, and 17 months following CFE (Table
V). Two patients were noted to have both iliac and SFA
disease in addition to the CFA restenosis. In both cases,
iliac and SFA disease were not present at the time of
preoperative angiograms (both done within 3 months of
CFE). Two patients had SFA disease in addition to the CFA
restenosis and only one patient had CFA as the only lesion
causing recurrent symptoms. All five failures were treated
with percutaneous endovascular therapy. Multivariate anal-
ysis showed congestive heart failure (CHF) as the only
predictor of primary failure (OR 18.5 [2.6-142.9]; P 
.004). There were no differences in primary patency rates
between patients presenting with claudication versus CLI,
between diabetic vs nondiabetic patients, between patients
undergoing isolated CFE versus hybrid procedures, or
between patients with untreated SFA disease versus those
without.Freedom from reintervention at 1 and 5 years were 82%
and 78%, respectively (Appendix II, online only). Again,
CHF was the only predictor of reintervention in the ipsilat-
eral limb (OR 5.3 [1.4-19.6]; P  .012] on multivariate
analysis. There were no differences in reintervention rates
between patients presenting with claudication vs CLI, be-
tween diabetic vs nondiabetic patients, between patients
undergoing isolated CFE vs hybrid procedures, or between
patients with untreated SFA disease vs those without.
Survival was 89% at 1 year and 70% at 5 years (Appendix
III, online only). No patient underwent a major or minor
amputation during the study period.
DISCUSSION
Previous studies on CFE have also shown favorable
results similar to those seen in our study.7,17-22 Mukherjee
et al reported 5-year patency rate of 94% on 29 patients
(41% CLI)18 and Springhorn et al reported 2- and 5-year
primary patency rates of 82% and 74%, respectively on 22
patients (69% CLI).19 In the latter study, failure was de-
fined as need for any further inflow procedures. However,
of the four patients considered to have primary failure, only
one patient was noted to have restenosis at the CFE site,
with the adjusted primary patency rate of 90% at both 2 and
5 years. Nelson et al examined 34 patients undergoing
combined EIA stenting and CFE (59% CLI).20 One-year
primary patency rate and primary-assisted patency rates
were 84% and 97%, respectively. More recently, Kechagias
et al examined 111 cases of isolated CFEs (31% CLI) and
reported 68% freedom from any ipsilateral revascularization
at 5 years.22 Unfortunately, this study did not look specif-
ically at the patency rates of the CFA segment. Taken
together, these studies demonstrate that CFE is a durable
procedure in the treatment of CFA occlusive disease.
In addition to the excellent long-term results of CFE,
this study also demonstrates its safety. In this study, we have
shown that procedural morbidity of CFE (5% major com-
plication) is comparable to those reported in recent studies
of infrainguinal PTAs (range 3.0% to 3.8%).3,5,6 Further-
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Fig 1. Primary and primary-assisted patency rates.more, most CFEs were performed under epidural or local
IA, co
roneal
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performed as an isolated procedure or in combination with
endovascular procedure. The low morbidity associated
with CFE likely negates any presumed advantage of endo-
vascular therapy over surgical endarterectomy. CFE seems
an attractive option even for those unfit for extensive bypass
grafts, especially those with extensive multilevel disease
where hybrid procedures can be performed by combining
CFE with endovascular treatment of iliac and/or infrain-
guinal lesions.
Over half of the cases in this study were performed as
a hybrid procedure. Compared with previous practice
wherein staged angiographic/surgical procedures were
employed,23 hybrid procedures offer not only efficiency but
also avoid operation in the region of a previously manipu-
lated femoral artery. We are increasingly utilizing MRA
rather than diagnostic angiography for preprocedure plan-
ning, followed by a hybrid procedure in the main operating
room equipped with fixed imaging. A surgically exposed
femoral artery offers better control and flexibility (eg, per-
forming inflow and outflow manipulations at the same
setting) during the endovascular part of the procedure.
The results of our study demonstrate that CFE with or
without inflow endovascular intervention is a reasonable
first step in treating patients with extensive femoropopliteal
lesion(s). Of the 25 cases with known femoropopliteal
lesions that were not treated at the time of CFE, 44% were
in those presenting with CLI. Furthermore, 48% of these
untreated lesions were TASC II C or D lesions. Treatment
of inflow lesions alone resulted in both symptomatic and
hemodynamic improvement, and freedom from reinterven-
tion in the ipsilateral limb was the same for those with or
without residual femoropopliteal lesion(s). Clearly, the
clinical circumstances will dictate the necessity (or lack
there of) for comprehensive distal revascularization. In the
presence of patent profunda and adequate collateralization,
treating any existing inflow lesions, including those in the
CFA, may be a reasonable first step in treating patients with
multilevel occlusive disease. Exception to this may be those
withmajor tissue loss, as our study did not have any patients
Table V. Primary failures
Initial procedure Failure
CFE 3 mo
CFE 5 mo
CIA/EIA PTA, CFE, SFA PTA 8 mo
EIA stent, CFE, SFA stent 12 mo
CFE, popliteal PTA 17 mo
CFE, Common femoral endarterectomy; PTA, percutaneous angioplasty; C
PFA, profunda femoral artery; SFA, superficial femoral artery; TPT, tibiopepresenting with Rutherford class 6 CLI.In treating restenosis of the CFA following CFE, we
routinely use PTA and this was indeed the case for all five
primary failures in this study. We believe that the nature of
the lesion at the time of restenosis (secondary to intimal
hyperplasia or clamp injury) is quite different from that of
the initial lesion. The native lesions in the CFA tend to be
heavily calcified and bulky, and angioplasty alone is often
inadequate whereas recurrent disease in the CFA is quite
well treated with balloon angioplasty.
Previous studies examining the efficacy of CFA PTA
demonstrate variable results and, clearly, additional data are
needed prior to assessing its long-term outcome. Of the
984 PTAs examined by Johnston et al, only 18 were
performed for lesions in the CFA. Primary patency rates at
1, 2, and 3 years in this subgroup were 59%, 49%, and 37%,
respectively.1 Silva et al examined 20 patients (43% CLI)
and reported event-free survival of 90% at follow-up (mean
follow-up 11.4 months), where event-free survival was
defined as freedom from death, amputation and target
vessel revascularization.8 The latter study is limited not only
by small sample size and limited follow-up, but also by lack
of objective measure, such as ABI or PVR, in assessing
efficacy of treatment. Neither of the above mentioned
studies report procedural morbidity associated with CFA
PTA. Among the 20 patients examined by Silva et al, one
patient died within the same hospitalization secondary to
sepsis (no further information given in the article).
Emerging endovascular techniques such as subintimal
angioplasty, laser angioplasty, and atherectomy, as well as
stent placement, may prove to be more effective than
balloon angioplasty in treating CFA lesions. There have
been reports of successful stent placement in the CFA.9,10
Following 33 cases of stent placement in the CFA bifurca-
tion, Stricker et al reported 1- and 3-year primary patencies
of 87% and 83%, respectively.9 However, majority of these
cases (82%) were for claudication and they report that only
a single, short (up to 4 cm) stent was used in each case.
Although not explicitly stated in the article, it appears that
the patients included in this study were those with very
limited, focal disease involving the CFA or the origin of
Reintervention
id-EIA severe stenosis ¡ PTA/stent
FA origin severe restenosis ¡ PTA
FA multiple focal stenosis ¡ PTA/stent
roximal CIA mod stenosis ¡ PTA
FA severe restenosis ¡ PTA
istal SFA severe stenosis ¡ PTA/stent
FA severe restenosis ¡ PTA
FA moderate restenosis ¡ PTA
FA severe restenosis (proximal end of prior stent) ¡ PTA/stent
FA origin severe restenosis ¡ PTA
FA severe stenosis x 2, multiple popliteal & TPT disease ¡ PTA
mmon iliac artery; EIA, external iliac artery; CFA, common femoral artery;
trunk.● m
● P
● S
● P
● C
● D
● C
● C
● S
● P
● SSFA or PFA. Until further data become available on these
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ferred treatment for lesions in the CFA in our practice.
This study is limited by its retrospective nature and
potential for referral bias given single institution catch-
ment. In addition, the lack of a “control” group treated
with endovascular methods (while reflecting our practice
and opinion about the preferred treatment) limits the scope
of conclusions referable to PTA and other endovascular
technologies. However, we believe that our study is among
the largest series clearly demonstrating favorable efficacy
and safety of CFE. In addition, it highlights the utilities and
advantages of hybrid procedures in patients with multilevel
occlusive disease. As newer endovascular technologies
emerge, comparative studies will be required.
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October 2008877.e1 Kang et alAppendix I, online only. Primary and assisted patency
Interval “At risk” # of events Cumulative patency Standard error
Primary patency 0-1 y 65 4 .93 .03
1-2 y 52 1 .91 .04
2-3 y 33 0 .91 .04
3-4 y 17 0 .91 .04
4-5 y 3 0 .91 .04
Assisted patency 0-1 y 65 0 1.00 .00
1-2 y 56 0 1.00 .00
2-3 y 36 0 1.00 .00
3-4 y 19 0 1.00 .00
4-5 y 3 0 1.00 .00Appendix II, online only. Freedom from reintervention in the ipsilateral limb
Interval “At risk” # of events Cumulative freedom Standard error
Freedom from reintervention 0-1 y 65 11 .82 .05
1-2 y 47 2 .78 .05
2-3 y 29 0 .78 .05
3-4 y 17 0 .78 .05
4-5 y 3 0 .78 .05Appendix III, online only. Survival
Interval “At risk” # of events Cumulative freedom Standard error
Survival 0-1 y 65 7 .89 .04
1-2 y 56 3 .83 .05
2-3 y 36 0 .83 .05
3-4 y 19 2 .70 .10
4-5 y 34 0 .70 .10
